Close Menu

NEW YORK ─ Invivoscribe said this week it has received an approval from the US Food and Drug Administration that enables it to distribute its LeukoStrat CDx FLT3 Mutation Assay as an in vitro diagnostic kit in the US.  

This premarket approval (PMA) supplement gives its customers an option to purchase the IVD-labeled LeukoStrat CDx FLT3 Mutation Assay with analysis software for in-house testing, Invivoscribe said.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Jul
14

This webinar will describe a rapid metagenomics assay under development for human pathogens, including the SARS-CoV-2 coronavirus.

Jul
15
Sponsored by
LGC SeraCare Life Sciences

Cancer immunotherapy is an exciting new advance for the successful treatment of many forms of metastatic cancer.

Jul
23

This webinar will discuss a study that set to assess the efficacy and safety of osimertinib in EGFR T790M positive non-small cell lung cancer (NSCLC) patients identified by using plasma sample and cobas EGFR Mutation test v2. This is the first prospective study to use liquid biopsy upfront to evaluate osimertinib efficacy.